



CTX-M-1 and CTX-M-15-producing *Escherichia coli* in dog faeces from public gardens

Damborg, Peter Panduro; Morsing, Malene Kjelin; Petersen, Tanja; Bortolaia, Valeria; Guardabassi, Luca

Published in:
Acta Veterinaria Scandinavica (Online)

DOI:
[10.1186/s13028-015-0174-3](https://doi.org/10.1186/s13028-015-0174-3)

Publication date:
2015

Document version
Publisher's PDF, also known as Version of record

Citation for published version (APA):
Damborg, P. P., Morsing, M. K., Petersen, T., Bortolaia, V., & Guardabassi, L. (2015). CTX-M-1 and CTX-M-15-producing *Escherichia coli* in dog faeces from public gardens. *Acta Veterinaria Scandinavica (Online)*, 57, [83].
<https://doi.org/10.1186/s13028-015-0174-3>

BRIEF COMMUNICATION

Open Access



CTX-M-1 and CTX-M-15-producing *Escherichia coli* in dog faeces from public gardens

Peter Damborg^{1*}, Malene Kjelin Morsing¹, Tanja Petersen¹, Valeria Bortolaia¹ and Luca Guardabassi^{1,2}

Abstract

Background: Extended-spectrum beta-lactamase (ESBL)-producing *Escherichia coli* are increasingly reported in dogs. The objective of this study was to provide data on the prevalence of ESBL-producing *E. coli* in dog faecal deposits in public gardens.

Results: A total of 209 faecal deposits collected in nine public gardens in Copenhagen, Denmark were screened by selective enrichment followed by plating on MacConkey agar supplemented with cefotaxime. Presumptive ESBL-producing *E. coli* were confirmed by MALDI-TOF MS and polymerase chain reaction (PCR) for detection of common cefotaxime resistance determinants (*bla*_{TEM}, *bla*_{SHV}, *bla*_{CTX-M} and *bla*_{CMY-2}). ESBL-producers were further characterized by multilocus sequence typing (MLST) and antimicrobial susceptibility testing using broth microdilution. Plasmids harbouring ESBL genes were characterized by S1 nuclease pulsed field gel electrophoresis, PCR-based replicon typing, and pMLST. Cefotaxime-resistant *E. coli* were detected in four (1.9 %) samples. Three samples harboured CTX-M-1-producing isolates, and one sample contained two CTX-M-15-producing isolates displaying distinct colony morphology. All isolates belonged to distinct sequence types (STs), including one *E. coli* lineage previously associated to a human-specific pathotype (ST59). *bla*_{CTX-M-1} was carried on IncI1 plasmids classified as ST3 or ST58 by pMLST, whereas *bla*_{CTX-M-15} was located on IncF/Y and non-typeable plasmids in the two strains isolated from the same sample.

Conclusions: The study shows that dog faeces are a vector for dissemination of CTX-M-producing *E. coli* within urban areas. The risk derived from human exposure to dog faeces in public gardens depends on the prevalence of these bacteria in the local dog population as well as on the owners' practice to remove and dispose their dog's faeces.

Keywords: ESBL, Canine, Environment, Antibiotic resistance, Zoonoses, CTX-M

Findings

The rapid emergence of extended-spectrum beta-lactamase (ESBL)-producing *Escherichia coli* in the community has prompted search for sources in the animal population. Food animals are a well-studied animal reservoir, but companion animals, in particular dogs, may also be colonised or infected with these cephalosporin-resistant *E. coli* [1]. The prevalence of ESBL carriage in dogs varies considerably between countries with the highest

frequency (55 %) being reported in diarrheic dogs in The Netherlands [2]. Faecal shedding of ESBL-producing *E. coli* by dogs was recently shown to be highly dynamic with the majority of dogs being intermittent shedders and positive for different ESBL genes over time [3]. The most common ESBL type found in canine *E. coli* is CTX-M, which also predominates in humans and other animals including livestock and wild animals [1, 4, 5].

The close contact between dogs and humans implies risks of zoonotic transmission for a variety of pathogens, especially by the faecal-oral route [6]. Dog faeces are a recognized source of zoonotic agents, including clinically relevant resistant bacteria that can be transmitted to humans through direct exposure or via contamination of

*Correspondence: pedam@sund.ku.dk

¹ Department of Veterinary Disease Biology, Faculty of Health and Medical Sciences, University of Copenhagen, Stigbøjlen 4, 1870 Frederiksberg, Denmark

Full list of author information is available at the end of the article

domestic and public environments. The objective of this study was to provide data on the prevalence and types of ESBL-producing *E. coli* in dog faecal deposits in public gardens.

In April and May 2013, 209 faecal samples were collected from trashcans in nine public gardens (5–40 samples per park) in the Greater Copenhagen area, Denmark. All samples were contained in plastic bags and supposedly less than 2 days old, since trashcans in these gardens are emptied at least every other day by the municipality. Each garden was visited only once to limit the risk of getting more than one sample per dog.

Samples were processed in the laboratory on the day of collection. One gram of each sample was suspended 1:10 in MacConkey broth (Oxoid, Basingstoke, UK) supplemented with 1 mg/l cefotaxime. Following overnight incubation with shaking at 37 °C, 10 µl of the enrichment culture was plated onto MacConkey agar (Oxoid) containing 1 mg/l cefotaxime. After incubation (24 h, 37 °C), one presumptive *E. coli* was sub-cultured from samples displaying growth and stored at –80 °C prior to further analyses. Multiple colonies were stored if more than one colony morphology was visible on the same plate.

Presumptive *E. coli* isolates were confirmed by matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) mass spectrometry (Vitek MS RUO; bioMérieux, France) using *E. coli* ATCC 8739 as reference strain and SaramisTM 3.5 (bioMérieux) for spectra interpretation. Antibiotic susceptibility was tested by broth microdilution using Sensititre COMPANIF plates (Thermo Fisher Scientific, Hvidovre, Denmark). Susceptibility to amoxicillin clavulanate, cefoxitin, cefpodoxime, imipenem, and the non-beta-lactams amikacin, chloramphenicol, doxycycline, enrofloxacin, gentamicin, marbofloxacin, and sulfamethoxazole/trimethoprim was interpreted according to the Clinical and Laboratory Standards Institute guidelines [7].

Genes encoding the most common ESBL types (*bla*_{CTX-M}, *bla*_{TEM} and *bla*_{SHV}) and plasmid-encoded AmpC beta-lactamase (*bla*_{CMY-2}) were detected by polymerase chain reaction (PCR) and sequenced [8, 9]. Positive isolates were characterized by multilocus sequence typing (MLST) and assigned to sequence types (STs) using the *E. coli* MLST database (<http://mlst-warwick.ac.uk>).

Plasmid DNA purified by alkaline lysis was transformed into electrocompetent *E. coli* (Invitrogen, Carlsbad, USA) followed by selection of transformants on Müller Hinton agar (Oxoid, Basingstoke, UK) supplemented with 1 mg/l cefotaxime. Transformants verified by colony PCR were subjected to S1 nuclease pulsed field gel electrophoresis (PFGE) [10], PCR-based replicon typing (PBRT) (Diatheva, Fano, Italy), and antimicrobial

susceptibility testing (as described above). IncI1 plasmids were subtyped by plasmid MLST (pMLST) [11].

Four faecal deposits (1.9 %) collected in two gardens displayed growth of lactose-positive colonies, and additional growth of lactose-negative colonies was detected in one of these samples. All colonies were identified as *E. coli* and harboured one or more genes encoding β-lactamase, namely *bla*_{CTX-M-1} (n = 3), *bla*_{CTX-M-15} (n = 2) and *bla*_{TEM-1} (n = 2) (Table 1). Each isolate belonged to a distinct genotype (ST59, ST609, ST4304, ST4305 or ST4340). The five strains were resistant to cefpodoxime and susceptible to amoxicillin clavulanate, cefoxitin, aminoglycosides and chloramphenicol. Susceptibility to fluoroquinolones, sulfamethoxazole/trimethoprim and doxycycline varied depending on the strain (Table 1).

Plasmids carrying ESBL genes varied from approximately 78 to 104 Kb. *bla*_{CTX-M-1} was found in three strains on IncI1 plasmids assigned to ST58 (n = 2) or ST3 (n = 1) by pMLST. *bla*_{CTX-M-15} was detected in the lactose-positive and the lactose-negative isolates from the same sample on distinct plasmids, one positive for both the FIB and the Y replicon types, and the other one non-typeable by PBRT. Resistance to sulfamethoxazole and trimethoprim was co-transferred by the two plasmids IncI1 ST3 and FIB/Y (Table 1).

The observed prevalence of 1.9 % ESBL-producing *E. coli* in dog faecal deposits is generally lower than reported in healthy dogs in other European studies [2, 12, 13]. This difference may indicate a low prevalence of ESBL-producing *E. coli* in the Danish dog population but could also be due to differences in study population, sample collection or processing. In fact, most other studies reported on fresh samples obtained directly from dogs. The high local variation with most ESBL-positive samples deriving from public garden B (Table 1) may reflect the relatively high number of samples (n = 40) collected in this garden, but otherwise is difficult to explain given the close proximity of the gardens (within a 7 km diameter zone) and the common municipal practice for emptying of waste bins. One recent study detected ESBL or AmpC-producing *E. coli* in 14 % of faecal deposits collected near a small animal hospital in Germany [14]. This high prevalence was likely influenced by the study location and associated antimicrobial selective pressure, since some clones were also detected in hospitalized dogs. Both that and the present study found a clear predominance of *bla*_{CTX-M-1} and *bla*_{CTX-M-15} among isolates, thus confirming previous evidence that these ESBL-types are the most frequent in dogs in Europe [1, 3, 15]. The ESBLs were found in different *E. coli* genetic backgrounds, including three newly described STs (ST4304, ST4305 and ST4340).

Table 1 Genotypic and phenotypic features of cefotaxime-resistant *Escherichia coli* isolated from dog faecal deposits

| Strain ID | Public garden | Faecal deposit | Cefotaxime-resistant <i>E. coli</i> | | | CTX-M-encoding plasmid | | | |
|-------------------|---------------|----------------|---|--------------------------------|-----------|------------------------|------------|-----------|---------------------------|
| | | | <i>bla</i> gene(s) | Resistance to non-beta-lactams | MLST type | Replicon(s) | pMLST type | Size (kb) | Co-transferred resistance |
| 147 | A | 1 | <i>bla</i> _{CTX-M-1} | None | ST59 | I1 | ST58 | 78 | None |
| 115 | B | 2 | <i>bla</i> _{CTX-M-1} | SXT | ST4340 | I1 | ST58 | 78 | None |
| 122 | B | 3 | <i>bla</i> _{CTX-M-1} <i>bla</i> _{TEM-1} | DOX, SXT | ST4304 | I1 | ST3 | 104 | SXT |
| 104g ^a | B | 4 | <i>bla</i> _{CTX-M-15} | ENR, MAR | ST4305 | Non-typeable | NA | 104 | None |
| 104r ^b | B | 4 | <i>bla</i> _{CTX-M-15} <i>bla</i> _{TEM-1} | DOX, SXT | ST609 | FIB, Y | NA | 95 | SXT |

ENR enrofloxacin, DOX doxycycline, MAR marbofloxacin, SXT sulfamethoxazole/trimethoprim, NA not applicable

^a Lactose-negative strain

^b Lactose-positive strain

and one genotype (ST59) that has previously been associated to a human-specific pathotype [16]. Our failure to detect CMY-2 was however unexpected, as this plasmid-mediated AmpC β -lactamase is frequent among cephalosporin-resistant *E. coli* isolated from dogs in Denmark [17] as well as in other EU countries [18] and continents [19–21].

The association of *bla*_{CTX-M-1} with IncI1 plasmids is well known in *E. coli* from humans and several animal species across Europe. Within this incompatibility group, ST3 plasmids harbouring *bla*_{CTX-M-1} have been reported in different animal species in Denmark, France, Switzerland and Tunisia [13, 22–25], suggesting that this specific IncI1 plasmid lineage has no geographic or host barriers. The other IncI1 plasmid detected in association with *bla*_{CTX-M-1} (ST58) plasmids is less frequently reported but was recently described in human CTX-M-1-producing *E. coli* isolates from Danish patients [24].

CTX-M-15 is the most frequent ESBL type in human clinical *E. coli* isolates in most EU countries, often in association with IncF plasmids [4]. We found *bla*_{CTX-M-15} on IncFIB/IncY and non-typeable plasmids in two genetically distinct *E. coli* strains originating from the same sample (Table 1). Multireplicon plasmid IncFIB/IncY have not been reported previously, although another hybrid replicon (IncY/IncA/C) was described in association with *bla*_{CTX-M-15} in *Salmonella* Concord isolated from humans in France [26]. Our results suggest that the dog from which the sample derived had been exposed to CTX-M-15-producing *E. coli* on at least two occasions or that recombination took place between different plasmids and strains. This second hypothesis is supported by the fact that the IncY replicon is also found on phages, and several plasmids non-typeable by PBRT in *E. coli* are indeed phages [27].

A limitation of the study is that samples were inside plastic bags upon collection and therefore not fully representing the faecal deposits that people may encounter on the ground. However, we deliberately chose this sampling strategy to minimize the risk of collecting samples from the same dog more than once.

The study shows that dog faeces are a vector for dissemination of CTX-M-producing *E. coli* within urban areas. The risk derived from human exposure to dog faeces in public gardens is highlighted by the isolation of *E. coli* and plasmid lineages previously detected in human infections. This risk appears to be low in Copenhagen but could be significantly higher in other geographical areas where these bacteria are prevalent in the dog population and the practice of removing and disposing dog faeces is not well established among dog owners. In view of this and the potential for other zoonotic pathogens in dog faeces [6], owners should be encouraged to dispose dog faecal deposits and to practice hand hygienic procedures afterwards, for example by using a hand rub disinfectant.

Abbreviations

ESBL: extended-spectrum beta-lactamase; MALDI-TOF MS: matrix-assisted laser desorption ionization-time of flight mass spectrometry; MLST: multilocus sequence typing; PFGE: pulsed field gel electrophoresis; PBRT: PCR-based replicon typing; pMLST: plasmid multilocus sequence typing; ST: sequence type.

Authors' contributions

LG conceived the study and planned the experiment together with PD. Sampling in public gardens was done by MKM and TP who also performed laboratory analyses and data interpretation along with PD and VB. All authors contributed to the final version of the manuscript. All authors have read and approved the final version of the manuscript.

Author details

¹ Department of Veterinary Disease Biology, Faculty of Health and Medical Sciences, University of Copenhagen, Stigbøjlen 4, 1870 Frederiksberg, Denmark.

² Department of Biomedical Sciences, Ross University School of Veterinary Medicine, Basseterre, St Kitts, West Indies.

Acknowledgements

Thanks to Ljudmila Troianova for excellent technical assistance. This study was supported by internal funding.

Competing interests

The authors declare that they have no competing interests.

Received: 16 September 2015 Accepted: 18 November 2015

Published online: 25 November 2015

References

- Ewers C, Bethe A, Semmler T, Guenther S, Wieler LH. Extended-spectrum β -lactamase-producing and AmpC-producing *Escherichia coli* from livestock and companion animals, and their putative impact on public health: a global perspective. *Clin Microbiol Infect*. 2012;18:646–55.
- Hordijk J, Schoormans A, Kwakernaak M, Duim B, Broens E, Dierikx C, et al. High prevalence of fecal carriage of extended spectrum β -lactamase/AmpC-producing Enterobacteriaceae in cats and dogs. *Front Microbiol*. 2013;4:242.
- Baede V, Wagenaar JA, Broens EM, Duim B, Dohmen W, Nijse R, et al. Longitudinal study of extended-spectrum- β -lactamase- and AmpC-producing Enterobacteriaceae in household dogs. *Antimicrob Agents Chemother*. 2015;59:3117–24.
- Livermore DM, Canton R, Gniadkowski M, Nordmann P, Rossolini GM, Arlet G, et al. CTX-M: changing the face of ESBLs in Europe. *J Antimicrob Chemother*. 2007;59:165–74.
- Guenther S, Ewers C, Wieler LH. Extended-spectrum beta-lactamases producing *E. coli* in wildlife, yet another form of environmental pollution? *Front Microbiol*. 2011;2:246.
- Damborg P, Broens EM, Chomel BB, Guenther S, Pasmans F, Wagenaar JA, et al. Bacterial zoonoses transmitted by household pets: state-of-the-art and future perspectives for targeted research and policy actions. *J Comp Pathol*. 2015. doi:10.1016/j.jcpa.2015.03.004.
- Clinical Laboratory Standards Institute (CLSI). Performance standards for antimicrobial disk and dilution susceptibility tests for bacteria isolated from animals; second informational supplement. CLSI document VET01S2. Wayne: CLSI; 2013.
- Hasman H, Mevius D, Veldman K, Olesen I, Aarestrup F. beta-lactamases among extended-spectrum beta-lactamase (ESBL)-resistant *Salmonella* from poultry, poultry products and human patients in the Netherlands. *J Antimicrob Chemother*. 2005;56:115–21.
- Pérez-Pérez FJ, Hanson ND. Detection of plasmid-mediated AmpC beta-lactamase genes in clinical isolates by using multiplex PCR. *J Clin Microbiol*. 2002;40:2153–62.
- Barton BM, Harding GP, Zuccarelli AJ. A general method for detecting and sizing large plasmids. *Anal Biochem*. 1995;226:235–40.
- García-Fernández A, Chiaretto G, Bertini A, Villa L, Fortini D, Ricci A, et al. Multilocus sequence typing of Inc11 plasmids carrying extended-spectrum beta-lactamases in *Escherichia coli* and *Salmonella* of human and animal origin. *J Antimicrob Chemother*. 2008;61:1229–33.
- Gandolfi-Decristophoris P, Petrini O, Ruggeri-Bernardi N, Schelling E. Extended-spectrum β -lactamase-producing Enterobacteriaceae in healthy companion animals living in nursing homes and in the community. *Am J Infect Control*. 2013;41:831–5.
- Haenni M, Saras E, Métayer V, Médaille C, Madec JY. High prevalence of *bla*_{CTX-M-1}/Inc11/ST3 and *bla*_{CMY-2}/Inc11/ST2 plasmids in healthy urban dogs in France. *Antimicrob Agents Chemother*. 2014;58:5358–62.
- Schäufli K, Bethe A, Lübke-Becker A, Ewers C, Kohn B, Wieler LH, et al. Putative connection between zoonotic multiresistant extended-spectrum beta-lactamase (ESBL)-producing *Escherichia coli* in dog feces from a veterinary campus and clinical isolates from dogs. *Infect Ecol Epidemiol*. 2015;5:25334.
- Huber H, Zweifel C, Wittenbrink MM, Stephan R. ESBL-producing uropathogenic *Escherichia coli* isolated from dogs and cats in Switzerland. *Vet Microbiol*. 2013;162:992–6.
- Mora A, López C, Dabhi G, Blanco M, Blanco JE, Alonso MP, et al. Extraintestinal pathogenic *Escherichia coli* O1:K1:H7/NM from human and avian origin: detection of clonal groups B2 ST95 and D ST59 with different host distribution. *BMC Microbiol*. 2009;9:132.
- Damborg P, Gaustad IB, Olsen JE, Guardabassi L. Selection of CMY-2 producing *Escherichia coli* in the faecal flora of dogs treated with cephalexin. *Vet Microbiol*. 2011;151:404–8.
- Bogaerts P, Huang TD, Bouchahrouf W, Baurain C, Berhin C, El Garch F, et al. Characterization of ESBL- and AmpC-producing Enterobacteriaceae from diseased companion animals in Europe. *Microb Drug Resist*. 2015. doi:10.1089/mdr.2014.0284.
- Bortolaia V, Hansen KH, Nielsen CA, Fritsche TR, Guardabassi L. High diversity of plasmids harbouring *bla*_{CMY-2} among clinical *Escherichia coli* isolates from humans and companion animals in the upper Midwestern USA. *J Antimicrob Chemother*. 2014;69:1492–6.
- Okubo T, Sato T, Yokota S, Usui M, Tamura Y. Comparison of broad-spectrum cephalosporin-resistant *Escherichia coli* isolated from dogs and humans in Hokkaido, Japan. *J Infect Chemother*. 2014;20:243–9.
- Rocha-Gracia RC, Cortés-Cortés G, Lozano-Zarain P, Bello F, Martínez-Laguna Y, Torres C. Faecal *Escherichia coli* isolates from healthy dogs harbour CTX-M-15 and CMY-2 β -lactamases. *Vet J*. 2015;203:315–9.
- Ben Sallem R, Ben Slama K, Rojo-Bezares B, Porres-Osante N, Jouini A, Klibi N, et al. Inc11 plasmids carrying *bla*_{CTX-M-1} or *bla*_{CMY-2} genes in *Escherichia coli* from healthy humans and animals in Tunisia. *Microb Drug Resist*. 2014;5:495–500.
- Dahmen S, Haenni M, Madec JY. Inc11/ST3 plasmids contribute to the dissemination of the *bla*_{CTX-M-1} gene in *Escherichia coli* from several animal species in France. *J Antimicrob Chemother*. 2012;67:3011–2.
- Jakobsen L, Bortolaia V, Bielak E, Moodley A, Olsen SS, Hansen DS, et al. Limited similarity between plasmids encoding CTX-M-1 beta-lactamase in *Escherichia coli* from humans, pigs, cattle, organic poultry layers and horses in Denmark. *J Glob Antimicrob Resist*. 2015;3:132–6.
- Zurfluh K, Wang J, Klumpp J, Nüesch-Inderbinen M, Fanning S, Stephan R. Vertical transmission of highly similar *bla*_{CTX-M-1}-harboring Inc11 plasmids in *Escherichia coli* with different MLST types in the poultry production pyramid. *Front Microbiol*. 2014;5:519.
- Fabre L, Delauné A, Espié E, Nygard K, Pardos M, Polomack L, et al. Chromosomal integration of the extended-spectrum beta-lactamase gene *bla*_{CTX-M-15} in *Salmonella enterica* serotype Concord isolates from internationally adopted children. *Antimicrob Agents Chemother*. 2009;53:1808–16.
- Billard-Pomares T, Fouteau S, Jacquet ME, Roche D, Barbe V, Castellanos M, et al. Characterization of a P1-like bacteriophage carrying an SHV-2 extended-spectrum β -lactamase from an *Escherichia coli* strain. *Antimicrob Agents Chemother*. 2014;58:6550–7.

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at
www.biomedcentral.com/submit

